Evidence map›Paper›PMID 40623898›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)].

Infectiology Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Society of Organ Transplantation, Chinese Society of Clinical Oncology Leukemia Expert Committee, Guangdong Medical Association of Respiratory Medicine, Guangdong Association of Primary Medicine Immunodeficiency Committee

Abstract readConsensus StatementEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Infectiology Group, Chinese Society of Hematology, Chinese Medical Association
Chinese Society of Organ Transplantation
Chinese Society of Clinical Oncology Leukemia Expert Committee
Guangdong Medical Association of Respiratory Medicine
Guangdong Association of Primary Medicine Immunodeficiency Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of immunocompromised individuals in China is rapidly increasing, and the incidence of cytomegalovirus (CMV) infection in this population is significantly higher than in the general population, severely affecting their quality of life and prognosis. Currently, a standardized diagnostic and treatment system for refractory/resistant CMV infections in immunocompromised populations is lacking. Based on domestic and international data on the epidemiology, evidence-based medicine, and clinical research regarding refractory/resistant CMV infections, this consensus formulates recommendations for the diagnosis, treatment, and management of these infections.

Indexed as

Cytomegalovirus InfectionsImmunocompromised HostAntiviral AgentsChinaConsensusCytomegalovirusDrug Resistance, ViralHumansAntiviral Agents

Identifiers

PMID40623898
PMCPMC12268285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.